ACE-gene polymorphism, particularly "D/I", may play a role in the occurrence of COVID-19 pneumonia in hypertensive elderly patients
Hakan Göçer1, Ahmet Barış Durukan21Department of Cardiology, Medical Park Uşak Hospital, Uşak, Turkey
2Department of Cardiovascular Surgery, Medical Park Uşak Hospital, Uşak, Turkey
Journal Title:Cardiovascular Surgery and Interventions
Renin-angiotensin-aldosterone system has an important role in the pathophysiology of high blood pressure. Also, angiotensin II and bradykinin are vasoactive molecules with multiple acute and chronic effects on the cardiovascular system.[1,2] As stated in recent reports, COVID-19 pneumonia more frequently occurs in COVID-19-positive hypertensive elderly. To the best our knowledge, COVID-19 pneumonia has a grave prognosis in hypertensive and elderly patients. Angiotensin-converting enzyme (ACE) genotype has been blamed for this course, and although the interaction between COVID-19 and ACE receptors interaction has been well defined, ACE genotype polymorphism has not been fully elucidated, yet. In this infection, many researches and reports have shown the effect of ACE insertion deletion (I/D) gene polymorphism on risk, prognosis, and reaction to treatment of many diseases such as hypertension, heart failure, myocardial infarction, diabetes, diabetic nephropathy, and cancer. It is well-known that ACE gene is located on chromosome 17 and polymorphism consists of three types within the intron 16 (DD, ID, II) and depends on heredity, ethnicity, and geographical considerations. Furthermore, D/I type has been found more frequently in hypertension, diabetes, and myocardial infarction. Prognosis is more grave in this genotype polymorphism. Our suggestion is that D/I type ACE gene polymorphism should be a research of interest for predicting prognosis and propensity of COVID-19 infection in hypertensive elderly patients.